Clinical experience: symptomatic management of BPH with terazosin.
Several reports in the literature have suggested that alpha-receptor blockade may have therapeutic value in treating the symptoms of patients with benign prostatic hypertrophy (BPH). Terazosin is an alpha-1 adrenergic blocking agent currently marketed as an antihypertensive. A multicenter study to evaluate the safety and efficacy of terazosin in the treatment of patients with BPH was initiated. Preliminary results in 15 patients showed that terazosin significantly improved peak as well as mean flow rates, and improved obstructive symptoms in patients with BPH (P less than 0.001). The results at four months of a six-month study support the conclusion that terazosin is beneficial for treatment of symptoms in patients with benign prostatic hypertrophy.
Dunzendorfer
U
U
Maingau Krankenhaus, Universität Frankfurt, West Germany.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D010919:Placebos; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013997:Time Factors; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; D010919:Placebos; C041226:Terazosin; D011224:Prazosin